SurModics (SRDX) Tops Q4 EPS by 15c

SurModics (NASDAQ: SRDX) reported Q4 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $24 million versus the consensus estimate of $23.06 million.

GUIDANCE:

SurModics sees FY2022 EPS of ($1.75)-($1.25), versus the consensus of $0.21. SurModics sees FY2022 revenue of $97-101 million, versus the consensus of $104.25 million.

For earnings history and earnings-related data on SurModics (SRDX) click here.

You May Also Be Interested In

• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
• William Blair on TransMedics Group (TMDX): 'We believe TransMedics’ second-quarter sales will exceed consensus estimates'
• ServiceNow to report Q2 2026 results on July 22